Detalles de la búsqueda
1.
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Invest New Drugs
; 36(4): 709-714, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488048
2.
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Invest New Drugs
; 34(6): 760-770, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27557783
3.
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Cancer
; 120(24): 3923-31, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25111199
4.
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Angiogenesis
; 15(2): 275-86, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22382585
5.
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients.
ScientificWorldJournal
; 2012: 420190, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22919317
6.
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.
Biochem Pharmacol
; 164: 94-105, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30953637
7.
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Oncol Rep
; 39(5): 2306-2314, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29517106
8.
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.
Invest New Drugs
; 30(4): 1725-30, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21509468
9.
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Cancer Lett
; 411: 35-43, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28964784
10.
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
Eur J Pharmacol
; 549(1-3): 27-34, 2006 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16978599
11.
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
Pharmacogenomics
; 17(1): 35-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26653034
12.
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
J Med Chem
; 59(13): 6547-52, 2016 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27305384
13.
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Oncotarget
; 6(30): 28743-54, 2015 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26337470
14.
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Eur J Med Chem
; 103: 29-43, 2015 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26318056
15.
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Eur J Pharmacol
; 498(1-3): 9-18, 2004 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-15363970
16.
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice.
In Vivo
; 28(1): 75-80, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24425839
17.
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
Target Oncol
; 9(3): 205-14, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23821377
18.
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.
Mol Cell Endocrinol
; 393(1-2): 56-64, 2014 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24931161
19.
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
J Clin Endocrinol Metab
; 99(4): E572-81, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24423321
20.
Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.
J Med Chem
; 57(4): 1225-35, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24447248